Sichuan Goldstone subsidiary Asia Pharmaceutical plans to increase its capital by 200 million yuan to Yak Pharmaceutical.
Jinshiya Medicine (300434.SZ) announced that, in accordance with the company's development strategy and its wholly-owned subsidiary Zhejiang Ya...
Sichuan Goldstone (300434.SZ) announced that, according to the company's development strategy and the business needs of its wholly-owned subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. ("Yake Pharmaceutical"), its wholly-owned subsidiary Hainan Asia Pharmaceutical Co., Ltd. ("Asia Pharmaceutical") plans to increase its capital by RMB 200 million to Yake Pharmaceutical using its own funds. After this capital increase is completed, Yake Pharmaceutical's registered capital will increase from RMB 1.5 billion to RMB 3.5 billion.
Related Articles
STREAM IDEAS (08401) has signed a strategic cooperation agreement with Shenzhen Shangshan Selection Supply Chain that does not have legal binding force.
SKYFAME REALTY (00059): Application for winding-up hearing adjournment.
Tsaker NE (01986) spent 14,800 Hong Kong dollars to repurchase 17,000 shares on July 4th.
STREAM IDEAS (08401) has signed a strategic cooperation agreement with Shenzhen Shangshan Selection Supply Chain that does not have legal binding force.
SKYFAME REALTY (00059): Application for winding-up hearing adjournment.
Tsaker NE (01986) spent 14,800 Hong Kong dollars to repurchase 17,000 shares on July 4th.
RECOMMEND
Anti-Overcompetition Drive Takes Hold Across Multiple Chinese Industries
04/07/2025
Bank of England Governor: Rise of Stablecoins May Undermine Confidence in National Currencies
04/07/2025
What the Passage of the “Big and Beautiful Act” Means for Americans: Gains and Losses Across Demographics
04/07/2025
